Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst

Galectin Therapeutics Inc. (NASDAQ:GALT) – Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Galectin Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce now expects that the company will earn ($0.19) per share for the quarter, up from their previous estimate of ($0.21). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($1.06) EPS.

Separately, StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th.

Galectin Therapeutics Stock Up 3.1 %

GALT opened at $1.32 on Monday. The business has a fifty day moving average of $1.46 and a 200 day moving average of $1.92. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $4.27. The stock has a market cap of $83.40 million, a P/E ratio of -1.81 and a beta of 0.79.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Monday, March 31st. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).

Institutional Trading of Galectin Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of GALT. Wealth Enhancement Advisory Services LLC raised its position in Galectin Therapeutics by 46.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company’s stock valued at $66,000 after purchasing an additional 16,412 shares in the last quarter. Vivaldi Capital Management LP raised its holdings in shares of Galectin Therapeutics by 89.9% in the fourth quarter. Vivaldi Capital Management LP now owns 45,628 shares of the company’s stock valued at $56,000 after acquiring an additional 21,596 shares in the last quarter. Bank of America Corp DE grew its holdings in Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock worth $49,000 after acquiring an additional 19,316 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Galectin Therapeutics by 4.3% in the 4th quarter. Northern Trust Corp now owns 244,274 shares of the company’s stock valued at $315,000 after purchasing an additional 9,994 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new stake in shares of Galectin Therapeutics in the 4th quarter valued at about $37,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.